Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

Overview of attention for article published in Journal of Neuro-Oncology, July 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 33,086 followers.

RT @JNeurooncol: Perifosine, an alkylophospholipid used to treat glioblastoma, may be tolerable, but is it effective? Check out this recent…

RT @JNeurooncol: Perifosine, an alkylophospholipid used to treat glioblastoma, may be tolerable, but is it effective? Check out this recent…

RT @JNeurooncol: Perifosine, an alkylophospholipid used to treat glioblastoma, may be tolerable, but is it effective? Check out this recent…

RT @JNeurooncol: Perifosine, an alkylophospholipid used to treat glioblastoma, may be tolerable, but is it effective? Check out this recent…

Perifosine, an alkylophospholipid used to treat glioblastoma, may be tolerable, but is it effective? Check out this recent article by Kaley and colleagues to find out more. #btsm #gbm #nsgy https://t.co/Tjw4iosBaV https://t.co/aaGn96Jb77

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. https://t.co/xMvEjgfm40